A herbal composition (hemohim) as a complementary agent for cancer radiotherapy and chemotherapy

HemoHIM significantly reduced the damage of liver and kidney by cisplatin. In a preliminary clinical study, 85 patients, diagnosed with breast or uterine cervix cancer, were administered with HemoHIM (6 g/day) for 12 weeks during radiation and/or chemotherapy. Age-matched 209 patients were monitored as control group. In the HemoHIM group, fewer cases of severe leucopenia (<3,000 leukocytes/mm³) were shown compared with the control group, and it was more evident in the breast cancer patients. In conclusion, HemoHIM may be a beneficial supplement during radiotherapy and chemotherapy for enhancing the anti-tumor efficacy and reducing the side effects